Department of Medical Biochemistry and Microbiology, Uppsala University, Box 582, Uppsala SE-751 23, Sweden.
Biochem Biophys Res Commun. 2010 Dec 10;403(2):198-202. doi: 10.1016/j.bbrc.2010.11.005. Epub 2010 Nov 5.
Protein C inhibitor (PCI) is a 57-kDa glycoprotein that exists in many tissues and secretions in human. As a member of the serpin superfamily of proteins it displays unusually broad protease specificity. PCI is implicated in the regulation of a wide range of processes, including blood coagulation, fertilization, prevention of tumors and pathogen defence. It has been reported that PCI isolated from human blood plasma is highly heterogeneous, and that this heterogeneity is caused by differences in N-glycan structures, N-glycosylation occupancy, and the presence of two forms that differ by the presence or absence of 6 amino acids at the amino-terminus. In this study we have verified that such heterogeneity exists in PCI purified from single individuals, and that individuals of two different ethnicities possess a similar PCI pattern, verifying that the micro-heterogeneity is conserved among humans. Furthermore, we have provided experimental evidence that PCI in both individuals is O-glycosylated on Thr20 with a core type 1 O-glycan, which is mostly NeuAcGalGalNAc. Modeling suggested that the O-glycan attachment site is located in proximity to several ligand-binding sites of the inhibitor.
蛋白 C 抑制剂 (PCI) 是一种 57kDa 的糖蛋白,存在于人类的许多组织和分泌物中。作为丝氨酸蛋白酶抑制剂超家族的一员,它表现出异常广泛的蛋白酶特异性。PCI 参与调节广泛的过程,包括血液凝固、受精、预防肿瘤和病原体防御。据报道,从人血浆中分离出的 PCI 高度不均一,这种不均一性是由 N-糖链结构、N-糖基化占有率以及两种形式的存在引起的,这两种形式在氨基末端存在或不存在 6 个氨基酸。在这项研究中,我们已经证实,从单个个体中纯化的 PCI 中存在这种不均一性,并且来自两个不同种族的个体具有相似的 PCI 模式,证实了这种微观不均一性在人类中是保守的。此外,我们提供了实验证据,证明两个人的 PCI 都在 Thr20 上发生 O-糖基化,形成核心 1 型 O-聚糖,主要是 NeuAcGalGalNAc。建模表明,O-聚糖的附着位点位于抑制剂的几个配体结合位点附近。